In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abcam PLC

www.abcam.com

Latest From Abcam PLC

Healx To Perk Up Industry's R&D Productivity Through The Power Of AI

Emerging Company Profile: Healx believes its development of relationships with rare disease patient groups combined with a multi-sourced database, which the UK start-up constructed using artificial intelligence technology, could transform the drug development process.

Rare Diseases Artificial Intelligence

Appointments: Crescendo, Shield, Sarepta, Verona, Hansa, Astellas and Pluristem

This week’s roundup includes various high-level appointments by companies including Vencerx Therapeutics, which has elected a new CEO, Shield Therapeutics, Crescendo Biologics, Pluristem Therapeutics, Sarepta Therapeutics and Verona Pharma.

Appointments BioPharmaceutical

Venture Funding Deals: New Cash For Delinia, Peloton, Fortis & Others

Moderna and Intarcia lead recent fundraisings; big pharma backing includes Novartis leading Series A for Inflazome and Pfizer for diabetes play Antolrx. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August through September 2016.

StartUps and SMEs Financing

CrownBio Aims For Gold Amid China Precision Medicines Rush

Another week has seen another plethora of deals between Chinese domestic players and global gene sequencing firms. Rising demand for individualized treatments and the rush for cancer immuno-therapies is propelling fast growth for the US-Chinese biotech company Crownbio, says its executive chairman Guo-Liang Yu.

China Personalized Medicine
See All

Company Information

  • Industry
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Abcam Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Abcam PLC
  • Senior Management
  • Alan Hirzel, CEO
    Jeff Iliffe, CFO
    Jim Warwick, COO
    Jonathan Milner, Deputy Chairman
  • Contact Info
  • Abcam PLC
    Phone: (44) (0)1223 696000
    330 Cambridge Science Pk.
    Cambridge, CB4 0FL
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register